Skip to content

Evaluating the effects of omega-3 on weight and depression

Evaluating effects of omega-3 supplementation on weight and depression among overweight or obese women with depression compared to placebo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014053016465N3
Enrollment
50
Registered
2014-06-16
Start date
2015-05-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Mild Depression. Condition 2: Moderate depression. Condition 3: Obseity. Mild depressive episode Two or three of the above symptoms are usually present. The patient is usually distressed by these but will probably be able to continue with most activities. Moderate depressive episode Four or more of the above symptoms are usually present and the patient is likely to have great difficulty in continuing with ordinary activities. Obesity due to excess calories

Interventions

Intervention 1: 3 gram omega-3 (2 capsules with each meal) for 12 weeks. Intervention 2: 2 placebo capsules with each meal for 12 weeks.
Treatment - Drugs
Placebo
3 gram omega-3 (2 capsules with each meal) for 12 weeks
2 placebo capsules with each meal for 12 weeks

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 57 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18 to 50 years; females; Body Mass Index above 25; patients with mild (minor) depression based on semi- structured diagnostic interview by a psychiatrist; to sign a consent form Exclusion Criteria: Those who are taking antidepressants; severe (major) depression; psychotic depression or have suicidal thoughts; use of anti-inflammatory glucocorticoids, and steroids; those who take medicines to reduce appetite or weight; those with diabetes who are taking medications or insulin; those with heart disease or hypercholesterolemia who are taking medication (statins, fibrates, diuretics); those how are taking oral anti-inflammatory drugs corticosteroids or any drug that causes weight loss or gain; taking hormonal contraceptives; pregnancy and lactation; menopause; severe mental disorder; schizophrenia and bipolar; hypothyroidism; exercise professionals; allergic to fish (due to Omega-3 supplements); those with special diets such as the diets for kidney disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Weight. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: Standard scales Seca.;Body Mass Index. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: kg/(m)2.;Depression. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: Hamilton rating scale for depression.

Secondary

MeasureTime frame
Central fat mass. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining. Method of measurement: Bioelectrical impadance.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed-Ali Mostafavi

Psychiatric Research Center

mostafavi.n80@hotmail.com+98 21 5541 3540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026